Latest news with #Biegler
Business Insider
4 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Bristol-Myers Squibb (BMY)
Analysts fell to the sidelines weighing in on Arvinas Holding Company (ARVN – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Arvinas Holding Company (ARVN) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Arvinas Holding Company yesterday. The company's shares closed last Friday at $7.20. According to Biegler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $14.66 average price target, implying a 95.5% upside from current levels. In a report released yesterday, Leerink Partners also downgraded the stock to Hold with a $9.00 price target. Bristol-Myers Squibb (BMY) Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb on May 31. The company's shares closed last Friday at $48.28. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Eli Lilly & Co. The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $55.53 average price target, representing a 16.0% upside. In a report issued on May 16, BMO Capital also maintained a Hold rating on the stock with a $53.00 price target.
Business Insider
4 days ago
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Gilead Sciences (GILD – Research Report). Confident Investing Starts Here: AbbVie (ABBV) In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Friday at $186.11. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.13, implying a 14.7% upside from current levels. In a report issued on May 30, Berenberg Bank also maintained a Hold rating on the stock with a $170.00 price target. Gilead Sciences (GILD) In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences, with a price target of $125.00. The company's shares closed last Friday at $110.08. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $120.47, implying a 7.9% upside from current levels. In a report issued on May 21, Jefferies also maintained a Buy rating on the stock with a $130.00 price target.
Business Insider
15-05-2025
- Business
- Business Insider
Oppenheimer Sticks to Its Buy Rating for Acrivon Therapeutics, Inc. (ACRV)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research Report) yesterday and set a price target of $9.00. The company's shares closed yesterday at $1.14. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -16.2% and a 27.06% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and IDEAYA Biosciences. Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $11.43. ACRV market cap is currently $37.63M and has a P/E ratio of -0.46. Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACRV in relation to earlier this year.
Business Insider
07-05-2025
- Business
- Business Insider
Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts fell to the sidelines weighing in on Day One Biopharmaceuticals (DAWN – Research Report) and InnovAge Holding (INNV – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Day One Biopharmaceuticals (DAWN) Oppenheimer analyst Matthew Biegler maintained a Hold rating on Day One Biopharmaceuticals today. The company's shares closed last Tuesday at $6.99. According to Biegler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.8% and a 28.1% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Zentalis Pharmaceuticals, and Arvinas Holding Company. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Day One Biopharmaceuticals with a $33.75 average price target. InnovAge Holding (INNV) William Blair analyst Ryan Daniels maintained a Hold rating on InnovAge Holding today. The company's shares closed last Tuesday at $2.85. According to Daniels is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Lifestance Health Group, and Pediatrix Medical Group. InnovAge Holding has an analyst consensus of Hold.
Yahoo
30-04-2025
- General
- Yahoo
Rejected for his mercy: Wyoming Catholics mourn Pope Francis
CHEYENNE — The Roman Catholic faith has entered a period of global transition, as parishioners globally mourn the passing of Pope Francis and prepare for the conclave, the process by which a new pope is elected. Known for his charity, humble nature, care for the poor and controversial, yet progressive stance on issues like LGBTQ+ rights and divorce, Francis passed on Easter Monday at 88 years old. In light of Pope Francis' passing, thousands of Catholics in the Cowboy State, whether they find themselves on the traditionalist or progressive side of the aisle, are in the midst of a nine-day period of prayer and mourning. Roughly 75 parishioners of the Roman Catholic Diocese of Cheyenne gathered early Tuesday morning at St. Mary's Cathedral to mourn Francis during a Mass for the Dead, led by Bishop Steven Biegler. Francis appointed Biegler as the ninth bishop of the Diocese of Cheyenne — which includes all of Wyoming — in 2017. 'Pope Francis said that the compassion of the Good Samaritan should be the order of lords, the order of love in our society, especially how we treat the poor and those on the margins, immigrants,' Biegler told attendees Tuesday morning. 'People didn't like that when he said that. He often was rejected because of the mercy he talked about.' Biegler added that Catholics should expect to be rejected if they are going to follow Christ, as the experience of rejection is one of the ways to proclaim the Gospel. 'People rejected Pope Francis when he proclaimed mercy for immigrants, members of the LGBTQ community, prisoners and the poor,' Biegler said. 'Mercy and rejection were part of Christ's life, profound mercy that led them also to be rejected. We should expect to be rejected if we're going to follow Christ and really show the kind of love that he showed.' Biegler further discussed the boldness with which Francis expressed his mercy, calling on congregants to embrace boldness in their own faith. 'Francis said that we needed to recapture the boldness, or the parrhesia. Parrhesia is the Greek word for that boldness,' Biegler said. '. … Boldness for the first disciples was based on their experience of the risen Lord, and we see it in the spirit which really put them on fire for Christ's presence.' Parishioner Nathaniel Trelease said he felt Biegler demonstrated his great affection for Francis and did 'a wonderful job' highlighting what the pope did in his ministry. 'Generally, popes do one of three things: They evangelize, they go and they preach the good news; they are focused on the public worship of God; or they express charity, care for the poor,' Trelease said. 'Pope Francis really focused on the third (charity). The bishop did a wonderful job of highlighting that outreach.' The entire Catholic Church is mourning the death of Pope Francis, according to a news release from the Diocese of Cheyenne. 'In cathedrals, basilicas, parish churches, shrines, and chapels, the Holy Eucharist will be offered for the repose of his soul,' the release reads. 'Communities and individuals will ask God to bestow his infinite mercy on the man who served the Church as Bishop of Rome.' While Catholics mourn the loss of Francis, the church also is preparing for the conclave, the process by which a new pope is selected, which will begin May 7. Just as there are ideological splits in politics, so are there ideological splits in the Roman Catholic Church. The selection of the new pope has implications for more than a billion members of the church worldwide. 'The hope for the conclave is the hope that we always have, which is to keep the Sacred Scripture and the deposit of faith alive and fresh for people 2000 years after the birth of Christ,' Trelease said. Though no Wyoming cardinals will be present for the vote, there are 10 American cardinals eligible to enter the conclave. There are roughly 135 cardinals eligible to vote. While the cardinals prepare for the conclave, the remainder of the church members can only faithfully pray for the cardinals to make the right decision. 'You hope that the Holy Spirit moves the cardinals in the conclave to make the right choice,' Trelease said. 'None of us here are wise enough to make that choice. But we all, whether in our individual lives or as princes of the church, have to be open to the promptings of the Spirit, and that's all we can hope for.'
